USD 2.3
↓ -0.13 (-5.35%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| NRBO | -5.3 | -14.8 | -9.1 | -41.0 | -45.8 | -33.2 | -99.5 | -99.9 | -100.0 | -100.0 |
| S&P 500 | -1.5 | -2.0 | 0.8 | 5.7 | 10.4 | 30.1 | 25.1 | 87.8 | 187.0 | 33076.6 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | NRBO |
| name | NeuroBo Pharmaceuticals, Inc. |
| price | 2.3 |
| changes percentage | -5.3498 |
| change | -0.13 |
| day low | 2.25 |
| day high | 2.46 |
| year high | 6.75 |
| year low | 2.08 |
| market cap | 19816823 |
| price avg 50 | 2.9652 |
| price avg 200 | 3.91668 |
| exchange | NASDAQ |
| volume | 23221 |
| avg volume | 44395 |
| open | 2.46 |
| previous close | 2.43 |
| eps | -4.01 |
| pe | -0.57 |
| earnings announcement | 2025-03-26T12:00:00.000+0000 |
| shares outstanding | 8616010 |
| timestamp | 2024-11-15 18:32:57 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001638287 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | -28000 | 100.00 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 9158000 | 2778000 | 229.66 |
| operating expenses | 15886000 | 11418000 | 39.13 |
| interest income | 461000 | 2191 | 20940.62 |
| interest expense | 0 | 2191000 | -100.00 |
| ebitda | -15880000 | -11398000 | -39.32 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -15886000 | -19628000 | 19.06 |
| operating income ratio | 0 | 0 | NaN |
| net income | -12470000 | -6115000 | -103.92 |
| net income ratio | 0 | 0 | NaN |
| eps | -2.46 | -19.01 | 87.06 |
Gross Profit: Gross Profit increased to 0 million in 2023 from 0 million in 2022 representing a change of 100.0%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 9 million in 2023 from 3 million in 2022 representing a change of 229.66%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -16 million in 2023 from -11 million in 2022 representing a change of -39.32%. The increase in EBITDA indicates improved operational efficiency and profitability.
Earnings per Share (EPS): EPS increased to -2.46 in 2023 from -2.46 in 2022 representing a change of 87.06%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 16 million in 2023 from 11 million in 2022 representing a change of 39.13%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Operating Income: Operating income decreased to -16 million in 2023 from -20 million in 2022 representing a change of 19.06%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -12 million in 2023 from -6 million in 2022 representing a change of -103.92%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001638287 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | -6000 | 100.00 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 4517000 | 8074000 | -44.05 |
| operating expenses | 6259000 | 10078000 | -37.89 |
| interest income | 310000 | 164000 | 89.02 |
| interest expense | 0 | 0 | NaN |
| ebitda | -6259000 | -10078000 | 37.89 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -6259000 | -10084000 | 37.93 |
| operating income ratio | 0 | 0 | NaN |
| net income | -5652000 | -10053000 | 43.78 |
| net income ratio | 0 | 0 | NaN |
| eps | -0.55 | -1.85 | 70.27 |
Gross Profit: Gross Profit increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 100.0%. This indicates a sales profitability growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -6 million in 2024Q3 from -10 million in 2024Q2 representing a change of 37.89%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -6 million in 2024Q3 from -10 million in 2024Q2 representing a change of 37.93%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -6 million in 2024Q3 from -10 million in 2024Q2 representing a change of 43.78%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.55 in 2024Q3 from -0.55 in 2024Q2 representing a change of 70.27%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 5 million in 2024Q3 from 8 million in 2024Q2 representing a change of -44.05%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 6 million in 2024Q3 from 10 million in 2024Q2 representing a change of -37.89%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001638287 | |||
| total assets | 22781000 | 33534000 | -32.07 |
| total liabilities | 6096000 | 11784000 | -48.27 |
| total equity | 16685000 | 21750000 | -23.29 |
| cash and cash equivalents | 22435000 | 33364000 | -32.76 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 22512000 | 33532000 | -32.86 |
| total non current assets | 269000 | 2000 | 13350.00 |
| total current liabilities | 5960000 | 11784000 | -49.42 |
| total non current liabilities | 136000 | 708000 | -80.79 |
| common stock | 5000 | 25000 | -80.00 |
| retained earnings | -108265000 | -95795000 | -13.02 |
| total debt | 203000 | 0 | NaN |
Total Assets: Total Assets decreased to 23 million in 2023 from 34 million in 2022 representing a change of -32.07%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 17 million in 2023 from 22 million in 2022 representing a change of -23.29%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 22 million in 2023 from 33 million in 2022 representing a change of -32.76%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 23 million in 2023 from 34 million in 2022 representing a change of -32.86%. This indicates a worsen liquidity position.
Common Stock: Common Stock decreased to 0 in 2023 from 0 in 2022 representing a change of -80.0%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -108 million in 2023 from -96 million in 2022 representing a change of -13.02%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 0 million in 2023 from 0 million in 2022 representing a change of nan%. This indicates an increase in overall debt burden.
Total Liabilities: Total Liabilities decreased to 6 million in 2023 from 12 million in 2022 representing a change of -48.27%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 6 million in 2023 from 12 million in 2022 representing a change of -49.42%. This indicates a lower short-term debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001638287 | |||
| total assets | 22146000 | 28751000 | -22.97 |
| total liabilities | 9193000 | 9809000 | -6.28 |
| total equity | 12953000 | 18942000 | -31.62 |
| cash and cash equivalents | 21669000 | 27934000 | -22.43 |
| short term investments | 0 | 111000 | -100.00 |
| long term investments | 0 | 0 | NaN |
| total current assets | 21935000 | 28517000 | -23.08 |
| total non current assets | 211000 | 234000 | -9.83 |
| total current liabilities | 9114000 | 9711000 | -6.15 |
| total non current liabilities | 79000 | 97999 | -19.39 |
| common stock | 9000 | 8000 | 12.50 |
| retained earnings | -130684000 | -125032000 | -4.52 |
| total debt | 154000 | 170000 | -9.41 |
Total Assets: Total Assets decreased to 22 million in 2024Q3 from 29 million in 2024Q2 representing a change of -22.97%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 13 million in 2024Q3 from 19 million in 2024Q2 representing a change of -31.62%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 22 million in 2024Q3 from 28 million in 2024Q2 representing a change of -22.43%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of -100.0%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 22 million in 2024Q3 from 29 million in 2024Q2 representing a change of -23.08%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -131 million in 2024Q3 from -125 million in 2024Q2 representing a change of -4.52%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 9 million in 2024Q3 from 10 million in 2024Q2 representing a change of -6.28%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 9 million in 2024Q3 from 10 million in 2024Q2 representing a change of -6.15%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2024Q3 from 0 in 2024Q2 representing a change of 12.5%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of -9.41%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001638287 | |||
| net change in cash | -10929000 | 16977000 | -164.38 |
| operating cash flow | -10799000 | -11712000 | 7.80 |
| free cash flow | -10849000 | -11712000 | 7.37 |
| capital expenditure | -50000 | 0 | NaN |
| depreciation and amortization | 6000 | 20000 | -70.00 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 222000 | 854 | 25895.32 |
| accounts payables | 113000 | -202000 | 155.94 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 8000 | -100.00 |
| investments in property plant and equipment | -50000 | 0 | NaN |
| net cash used for investing activites | -50000 | 8000 | -725.00 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -80000 | 32250000 | -100.25 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -80000 | 28681 | -378.93 |
| cash at end of period | 22435000 | 33364000 | -32.76 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 33364000 | 16387000 | 103.60 |
Net Change in Cash: Net Change in Cash decreased to -11 million in 2023 from 17 million in 2022 representing a change of -164.38%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Stock-Based Compensation: Stock-Based Compensation increased to 0 million in 2023 from 0 million in 2022 representing a change of 25895.32%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Operating Cash Flow: Operating Cash Flow increased to -11 million in 2023 from -12 million in 2022 representing a change of 7.8%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -11 million in 2023 from -12 million in 2022 representing a change of 7.37%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2023 from 0 million in 2022 representing a change of nan%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2023 from 0 million in 2022 representing a change of 155.94%. This indicates that the company has reduced its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001638287 | |||
| operating cash flow | -5589000 | -7251000 | 22.92 |
| free cash flow | -5589000 | -7254000 | 22.95 |
| capital expenditure | 0 | -3000 | 100.00 |
| depreciation and amortization | 5000 | 6000 | -16.67 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 243895 | 134000 | 82.01 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | -1374000 | 138000 | -1095.65 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | -3000 | 100.00 |
| net cash used for investing activites | 19998000 | -3000 | 666700.00 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -19159000 | 19200000 | -199.79 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -676000 | 19200000 | -103.52 |
| net change in cash | -6265000 | 11946000 | -152.44 |
| cash at end of period | 21669000 | 27934000 | -22.43 |
| cash at beginning of period | 27934000 | 15988000 | 74.72 |
Net Change in Cash: Net Change in Cash decreased to -6 million in 2024Q3 from 12 million in 2024Q2 representing a change of -152.44%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 100.0%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 82.01%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 1 million in 2024Q3 from 0 million in 2024Q2 representing a change of -1095.65%. This indicates that the company has increased its outstanding obligations to its suppliers.
Operating Cash Flow: Operating Cash Flow increased to -6 million in 2024Q3 from -7 million in 2024Q2 representing a change of 22.92%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -6 million in 2024Q3 from -7 million in 2024Q2 representing a change of 22.95%. This indicates an increase in cash generated after accounting for capital expenditures.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -2.46 | -19.01 | 87.06 |
| operating cash flow per share | -2.13 | -36.41 | 94.15 |
| free cash flow per share | -2.14 | -36.41 | 94.12 |
| cash per share | 4.43 | 103.71 | -95.73 |
| book value per share | 3.29 | 67.61 | -95.13 |
| tangible book value per share | 3.29 | 67.61 | -95.13 |
| shareholders equity per share | 3.29 | 67.61 | -95.13 |
| interest debt per share | 0.01 | 6.81 | -99.81 |
| market cap | 18755300 | 1846575.22 | 915.68 |
| enterprise value | -3476700 | -31517424.78 | 88.97 |
| pe ratio | -1.5 | -0.3 | -398.07 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -1.74 | -0.16 | -1001.55 |
| pfcf ratio | -1.73 | -0.16 | -996.47 |
| pb ratio | 1.12 | 0.08 | 1224.01 |
| ptb ratio | 1.12 | 0.08 | 1224.01 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | 0.22 | 2.77 | -92.08 |
| ev to operating cash flow | 0.32 | 2.69 | -88.04 |
| ev to free cash flow | 0.32 | 2.69 | -88.09 |
| earnings yield | -0.66 | -3.31 | 79.92 |
| free cash flow yield | -0.58 | -6.34 | 90.88 |
| debt to equity | 0.0 | 0 | NaN |
| debt to assets | 0.0 | 0 | NaN |
| net debt to ebitda | 1.4 | 2.93 | -52.17 |
| current ratio | 3.78 | 2.85 | 32.74 |
| interest coverage | 0 | -8.96 | 100.00 |
| income quality | 0.87 | 0.84 | 3.27 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 8.33 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 13.5 | 170.05 | -92.06 |
| roic | -0.95 | -0.4 | -140.01 |
| return on tangible assets | -0.55 | -0.18 | -200.18 |
| graham net net | 3.22 | 67.08 | -95.19 |
| working capital | 16552000 | 21748000 | -23.89 |
| tangible asset value | 16685000 | 21750000 | -23.29 |
| net current asset value | 16416000 | 21748000 | -24.52 |
| invested capital | 16800000 | 21750000 | -22.76 |
| average receivables | 0 | 0 | NaN |
| average payables | 764500 | 769000 | -0.59 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 9229.29 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0.04 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.75 | -0.28 | -165.83 |
| capex per share | 0.01 | 0 | NaN |
ROE: Return on Equity (ROE) decreased to -0.75 on 2023-12-31 from -0.28 on 2022-12-31, representing a change of -165.83%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -1.50 on 2023-12-31 from -0.30 on 2022-12-31, representing a change of -398.07%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 3.78 on 2023-12-31 from 2.85 on 2022-12-31, representing a change of 32.74%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| NRBO | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -0.55 | -1.85 | 70.12 |
| operating cash flow per share | -0.55 | -1.34 | 59.03 |
| free cash flow per share | -0.55 | -1.34 | 59.05 |
| cash per share | 2.12 | 5.17 | -58.93 |
| book value per share | 1.27 | 3.49 | -63.65 |
| tangible book value per share | 1.27 | 3.49 | -63.65 |
| shareholders equity per share | 1.27 | 3.49 | -63.65 |
| interest debt per share | 0.02 | 0.01 | 13.68 |
| market cap | 32378655.79 | 24647233.24 | 31.37 |
| enterprise value | 10863655.79 | -3116766.76 | 448.56 |
| pe ratio | -1.43 | -0.61 | -133.66 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -5.79 | -3.4 | -70.43 |
| pfcf ratio | -5.79 | -3.4 | -70.50 |
| pb ratio | 2.5 | 1.3 | 92.11 |
| ptb ratio | 2.5 | 1.3 | 92.11 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -1.74 | 0.31 | -661.23 |
| ev to operating cash flow | -1.94 | 0.43 | -552.21 |
| ev to free cash flow | -1.94 | 0.43 | -552.39 |
| earnings yield | -0.17 | -0.41 | 57.20 |
| free cash flow yield | -0.17 | -0.29 | 41.35 |
| debt to equity | 0.01 | 0.0 | 212.78 |
| debt to assets | 0.01 | 0.0 | 177.68 |
| net debt to ebitda | 3.44 | 2.75 | 24.78 |
| current ratio | 2.41 | 2.94 | -18.04 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.99 | 0.72 | 37.10 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | 0 | -0.0 | 100.00 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0.5 | -100.00 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 3.97 | 12.06 | -67.04 |
| roic | -0.48 | -0.53 | 9.96 |
| return on tangible assets | -0.26 | -0.35 | 27.01 |
| graham net net | 1.22 | 3.36 | -63.64 |
| working capital | 12821000 | 18806000 | -31.82 |
| tangible asset value | 12953000 | 18942000 | -31.62 |
| net current asset value | 12742000 | 18708000 | -31.89 |
| invested capital | 13011000 | 19019000 | -31.59 |
| average receivables | 0 | 36500 | -100.00 |
| average payables | 1824500 | 2355500 | -22.54 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 39480 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0.0 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.44 | -0.53 | 17.78 |
| capex per share | 0 | 0.0 | -100.00 |
ROE: Return on Equity (ROE) increased to -0.44 on 2024-09-30 Q3 from -0.53 on 2024-06-30 Q2, representing a change of 17.78%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -1.43 on 2024-09-30 Q3 from -0.61 on 2024-06-30 Q2, representing a change of -133.66%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 2.41 on 2024-09-30 Q3 from 2.94 on 2024-06-30 Q2, representing a change of -18.04%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.01 on 2024-09-30 Q3 from 0.00 on 2024-06-30 Q2, representing a change of 212.78%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Positive Sentiment: Discounted Cash Flow value is 4.38 which is higher than current price 2.3, indicates the company may be undervalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-13 08:01:00
CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following investor conferences in November: November 14:Â Life Science Virtual Investor Forum.
Sentiment: Positive
Publish Date: 2024-11-07 08:01:00
Reported Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity, Revealing Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics $21.7 Million in Cash at  End of Third Quarter E xpected to Fund the Company Into the Third Quarter of 2025 Top-Line Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH Expected in December of 2024 Top-Line Data From the MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in the First Quarter of 2025 Entered into a Joint Research Agreement, Together With Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 CAMBRIDGE, Mass. , Nov. 7, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update.
Sentiment: Positive
Publish Date: 2024-11-04 08:01:00
Topline Data Readout From Part 1 and Part 2 Expected in December 2024 CAMBRIDGE, Mass. , Nov. 4, 2024 /PRNewswire/ --Â NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of the last patient last visit in its two-part, Phase 2a clinical trial evaluating the efficacy and safety of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Sentiment: Positive
Publish Date: 2024-10-01 08:01:00
CAMBRIDGE, Mass. , Oct. 1, 2024 /PRNewswire/ --Â NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that management will participate in the following investor conferences in October: October 7: H.C.
Sentiment: Positive
Publish Date: 2024-09-30 08:01:00
Data Revealed Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics (PK) Top-Line Data Readout from the MAD Part 2 Expected in the First Quarter of 2025 Planned Phase 1 Part 3 Will Evaluate Early Proof of Concept CAMBRIDGE, Mass. , Sept. 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive top-line safety, tolerability, and dose-linear pharmacokinetics (PK) data from the single ascending dose (SAD) Part 1 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.
Sentiment: Positive
Publish Date: 2024-09-03 08:01:00
CAMBRIDGE, Mass. , Sept. 3, 2024 /PRNewswire/ --Â NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
